|
US20030114410A1
(en)
|
2000-08-08 |
2003-06-19 |
Technion Research And Development Foundation Ltd. |
Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
|
|
GB0521139D0
(en)
*
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
|
IN2014DN10515A
(enExample)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
CL2007001665A1
(es)
|
2006-06-08 |
2008-01-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
|
|
ES2402334T3
(es)
|
2007-08-02 |
2013-04-30 |
Gilead Biologics, Inc |
Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
|
|
DK3059246T3
(en)
|
2007-09-26 |
2018-10-01 |
Chugai Pharmaceutical Co Ltd |
Modified constant region of an antibody
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
MY185647A
(en)
|
2007-12-05 |
2021-05-27 |
Chugai Pharmaceutical Co Ltd |
Therapeutic agent for pruritus
|
|
BRPI0821110B8
(pt)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
|
|
TWI700293B
(zh)
|
2008-04-11 |
2020-08-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗體
|
|
JP5646457B2
(ja)
*
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
|
AR072000A1
(es)
*
|
2008-06-03 |
2010-07-28 |
Abbott Lab |
Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
|
|
BRPI0915448A2
(pt)
*
|
2008-07-08 |
2015-11-10 |
Abbott Lab |
imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
|
|
KR20160062207A
(ko)
*
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항ｎｒ１０ 항체 및 그의 이용
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
US9107935B2
(en)
|
2009-01-06 |
2015-08-18 |
Gilead Biologics, Inc. |
Chemotherapeutic methods and compositions
|
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
AU2010242840B2
(en)
*
|
2009-05-01 |
2014-04-17 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
SG178845A1
(en)
|
2009-08-21 |
2012-04-27 |
Gilead Biologics Inc |
Catalytic domains from lysyl oxidase and loxl2
|
|
TW201119676A
(en)
*
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
SG187938A1
(en)
|
2010-08-26 |
2013-04-30 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
KR102568454B1
(ko)
|
2010-11-30 |
2023-08-18 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
|
WO2013063186A2
(en)
*
|
2011-10-26 |
2013-05-02 |
Novartis Animal Health Us, Inc. |
Monoclonal antibodies and methods of use
|
|
CN104159920A
(zh)
|
2011-12-30 |
2014-11-19 |
艾伯维公司 |
针对il-13和/或il-17的双重可变结构域免疫球蛋白
|
|
MY171664A
(en)
|
2012-11-01 |
2019-10-22 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
|
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
|
|
WO2015077826A1
(en)
*
|
2013-11-27 |
2015-06-04 |
Welcome Receptor Antibodies Pty Ltd |
Marker of cell death
|
|
CA2960756C
(en)
|
2014-09-15 |
2023-08-01 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
MA43918A
(fr)
|
2015-04-14 |
2018-12-05 |
Chugai Pharmaceutical Co Ltd |
Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
|
|
TWI799849B
(zh)
|
2015-04-24 |
2023-04-21 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
GB201509907D0
(en)
*
|
2015-06-08 |
2015-07-22 |
Urosens Ltd |
Antibodies
|
|
EP4060344A1
(en)
|
2015-06-08 |
2022-09-21 |
Arquer Diagnostics Limited |
Methods and kits
|
|
JP6854246B2
(ja)
|
2015-06-08 |
2021-04-07 |
アーケア ダイアグノスティクス リミテッド |
尿サンプルの分析方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
WO2017184942A1
(en)
*
|
2016-04-21 |
2017-10-26 |
Abbvie Stemcentrx Llc |
Novel anti-bmpr1b antibodies and methods of use
|
|
GB201707938D0
(en)
|
2017-05-17 |
2017-06-28 |
Univ Sheffield |
Compounds
|
|
MX2020010320A
(es)
|
2018-04-02 |
2021-01-08 |
Amgen Inc |
Composiciones de erenumab y usos de las mismas.
|
|
CN113272322A
(zh)
*
|
2018-10-08 |
2021-08-17 |
Uab 研究基金会 |
神经内分泌癌靶向治疗
|
|
GB201818651D0
(en)
|
2018-11-15 |
2019-01-02 |
Univ Sheffield |
Compounds
|
|
GB201818649D0
(en)
|
2018-11-15 |
2019-01-02 |
Univ Sheffield |
Compounds
|
|
EP4062933A4
(en)
|
2019-11-20 |
2023-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
CN112920267B
(zh)
*
|
2021-03-09 |
2021-08-13 |
北京康乐卫士生物技术股份有限公司 |
一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用
|
|
EP4615452A1
(en)
*
|
2022-11-10 |
2025-09-17 |
The Children's Medical Center Corporation |
Cgrp/ramp1 blockade to treat endometriosis-associated pain and reduce endometriosis lesions
|
|
GB202303531D0
(en)
*
|
2023-03-10 |
2023-04-26 |
Fusion Antibodies Plc |
Antibodies and uses thereof
|
|
WO2026052977A1
(en)
|
2024-09-09 |
2026-03-12 |
Finn Therapeutics Ltd. |
Antibodies binding receptor activity-modifying protein (ramp)-3 and uses thereof
|